A radiomics nomogram model for predicting prognosis of pancreatic ductal adenocarcinoma after high-intensity focused ultrasound surgery

References

• Mcguigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–4861.
   PubMed Web of Science ®Google Scholar
• Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694–9705.
   PubMed Web of Science ®Google Scholar
• Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378(9791):607–620.
   PubMed Web of Science ®Google Scholar
• VON Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• VAN DEN Bijgaart RJ, Eikelenboom DC, Hoogenboom M, et al. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother. 2017;66(2):247–258.
   PubMed Web of Science ®Google Scholar
• Mihcin S, Melzer A. Principles of focused ultrasound. Minim Invasive Ther Allied Technol. 2018;27(1):41–50.
   PubMed Web of Science ®Google Scholar
• Tao SF, Gu WH, Gu JC, et al. A retrospective case series of high-intensity focused ultrasound (HIFU) in combination with gemcitabine and oxaliplatin (Gemox) on treating elderly middle and advanced pancreatic cancer. OncoTargets Ther. 2019;12:9735–9745.
   PubMed Web of Science ®Google Scholar
• Li CC, Wang YQ, Li YP, et al. High-intensity focused ultrasound for treatment of pancreatic cancer: a systematic review. J Evid Based Med. 2014;7(4):270–281.
   PubMedGoogle Scholar
• Xiaoping L, Leizhen Z. Advances of high intensity focused ultrasound (HIFU) for pancreatic cancer. Int J Hyperthermia. 2013;29(7):678–682.
   PubMed Web of Science ®Google Scholar
• Ren S, Zhao R, Zhang J, et al. Diagnostic accuracy of unenhanced CT texture analysis to differentiate mass-forming pancreatitis from pancreatic ductal adenocarcinoma. Abdom Radiol. 2020;45(5):1524–1533.
   PubMed Web of Science ®Google Scholar
• Guo C, Zhuge X, Wang Q, et al. The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis. Cancer Imaging. 2018;18(1):37.
   PubMedGoogle Scholar
• Qiu W, Duan N, Chen X, et al. Pancreatic ductal adenocarcinoma: machine learning-based quantitative computed tomography texture analysis for prediction of histopathological grade. Cancer Manag Res. 2019;11:9253–9264.
   PubMed Web of Science ®Google Scholar
• Choi MH, Lee YJ, Yoon SB, et al. MRI of pancreatic ductal adenocarcinoma: texture analysis of T2-weighted images for predicting long-term outcome. Abdom Radiol. 2019;44(1):122–130.
   PubMed Web of Science ®Google Scholar
• Kim BR, Kim JH, Ahn SJ, et al. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis. Eur Radiol. 2019;29(1):362–372.
   PubMed Web of Science ®Google Scholar
• Attiyeh MA, Chakraborty J, Doussot A, et al. Survival prediction in pancreatic ductal adenocarcinoma by quantitative computed tomography image analysis. Ann Surg Oncol. 2018;25(4):1034–1042.
   PubMed Web of Science ®Google Scholar
• Kaissis G, Ziegelmayer S, Lohöfer F, et al. A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. Eur Radiol Exp. 2019;3(1):41.
   PubMedGoogle Scholar
• Dhillon J, Betancourt M. Pancreatic ductal adenocarcinoma. Monogr Clin Cytol. 2020;26:74–91.
   PubMedGoogle Scholar
• Nsingwane Z, Candy G, Devar J, et al. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects. Mol Biol Rep. 2020;47(8):6269–6280.
   PubMed Web of Science ®Google Scholar
• Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci. 2017;18(7):1338.
   PubMed Web of Science ®Google Scholar
• Springfeld C, Jäger D, Büchler MW, et al. Chemotherapy for pancreatic cancer. Presse Med. 2019;48(3 Pt 2):e159–e174.
   PubMed Web of Science ®Google Scholar
• Ning Z, Xie J, Chen Q, et al. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. OncoTargets Ther. 2019;12:1021–1029.
   PubMed Web of Science ®Google Scholar
• Guo J, Wang Y, Chen J, et al. Systematic review and trial sequential analysis of high-intensity focused ultrasound combined with chemotherapy versus chemotherapy in the treatment of unresectable pancreatic ductal adenocarcinoma. Int J Hyperthermia. 2021;38(1):1375–1383.
   PubMed Web of Science ®Google Scholar
• Lafond M, Lambin T, Drainville RA, et al. Pancreatic ductal adenocarcinoma: current and emerging therapeutic uses of focused ultrasound. Cancers. 2022;14(11):2557.
   PubMed Web of Science ®Google Scholar
• Sofuni A, Asai Y, Tsuchiya T, et al. Novel therapeutic method for unresectable pancreatic cancer-the impact of the long-term research in therapeutic effect of high-intensity focused ultrasound (HIFU) therapy. Curr Oncol. 2021;28(6):4845–4861.
   PubMed Web of Science ®Google Scholar
• Herreros-Villanueva M, Ruiz-Rebollo L, Montes M, et al. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort. Mol Biol Rep. 2020;47(3):1583–1588.
   PubMed Web of Science ®Google Scholar
• Loosen SH, Neumann UP, Trautwein C, et al. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol. 2017;39(6):1010428317692231.
   Google Scholar
• Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441–446.
   PubMed Web of Science ®Google Scholar
• Verma V, Simone CB II, Krishnan S, et al. The rise of radiomics and implications for oncologic management. J Natl Cancer Inst. 2017;109(7):djx055.
   Google Scholar
• Mayerhoefer ME, Materka A, Langs G, et al. Introduction to radiomics. J Nucl Med. 2020;61(4):488–495.
   PubMed Web of Science ®Google Scholar
• Giambelluca D, Cannella R, Vernuccio F, et al. PI-RADS 3 lesions: role of prostate MRI texture analysis in the identification of prostate cancer. Curr Probl Diagn Radiol. 2021;50(2):175–185.
   PubMed Web of Science ®Google Scholar
• Ma W, Ji Y, Qi L, et al. Breast cancer Ki67 expression prediction by DCE-MRI radiomics features. Clin Radiol. 2018;73(10):909.e1–909.e5.
   PubMed Web of Science ®Google Scholar
• Jain P, Khorrami M, Gupta A, et al. Novel non-invasive radiomic signature on CT scans predicts response to platinum-based chemotherapy and is prognostic of overall survival in small cell lung cancer. Front Oncol. 2021;11:744724.
   PubMedGoogle Scholar
• Benedetti G, Mori M, Panzeri MM, et al. CT-derived radiomic features to discriminate histologic characteristics of pancreatic neuroendocrine tumors. La Radiol Med. 2021;126(6):745–760.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim SH, Park HK, et al. Pancreatic ductal adenocarcinoma: rim enhancement at MR imaging predicts prognosis after curative resection. Radiology. 2018;288(2):456–466.
   PubMed Web of Science ®Google Scholar
• He Y, Hu B, Zhu C, et al. A novel multimodal radiomics model for predicting prognosis of resected hepatocellular carcinoma. Front Oncol. 2022;12:745258.
   PubMedGoogle Scholar
• Cen C, Liu L, Li X, et al. Pancreatic ductal adenocarcinoma at CT: a combined nomogram model to preoperatively predict cancer stage and survival outcome. Front Oncol. 2021;11:594510.
   PubMed Web of Science ®Google Scholar
• Xie T, Wang X, Li M, et al. Pancreatic ductal adenocarcinoma: a radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection. Eur Radiol. 2020;30(5):2513–2524.
   PubMed Web of Science ®Google Scholar
• Liang W, Yang P, Huang R, et al. A combined nomogram model to preoperatively predict histologic grade in pancreatic neuroendocrine tumors. Clin Cancer Res. 2019;25(2):584–594.
   PubMed Web of Science ®Google Scholar
• Cheng SH, Cheng YJ, Jin ZY, et al. Unresectable pancreatic ductal adenocarcinoma: role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Eur J Radiol. 2019;113:188–197.
   PubMed Web of Science ®Google Scholar